| Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement? | |
| | |
MedLine Citation:
|
PMID: 20518809 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
AIM: The benefit of direct, as opposed to calculated, low density lipoprotein -cholesterol (LDL-C) measurement remains unclear. This study compared the biological variability of direct LDL in patients with type 2 diabetes (T2DM) on equivalent doses of the short half-life statin, simvastatin or the longer half-life statin, atorvastatin. METHODS: A cross-over study of biological variation of lipids in 26 patients with T2DM taking either simvastatin 40 mg (n = 10) or atorvastatin 10 mg. After 3 months on one statin, fasting lipids were measured on 10 occasions over a 5-week period. The same procedure was then followed on the other statin. The variability of LDL-C was established using a Beckman direct assay. RESULTS: As a group, mean LDL was no different between statins (mean +/- s.d.) (1.69 +/- 0.60 mmol/l simvastatin vs. 1.67 +/- 0.60 mmol/l atorvastatin, p = 0.19). However, in all patients, the intraindividual biological variability of LDL while taking simvastatin was markedly higher than with atorvastatin (average s.d. = 0.17 mmol /l simvastatin vs. 0.01 mmol/l, p < 0.0001). Friedewald calculated LDL variability was no different between statins (average s.d. = 0.34 mmol /l simvastatin vs. 0.21 mmol/l atorvastatin, p = 0.19). CONCLUSIONS: In contrast to calculated values, direct measurement revealed LDL to be much more stable (the s.d. being an order of magnitude) in T2DM patients taking atorvastatin rather than simvastatin. This means LDL targets can be consistently met with less lipid monitoring using atorvastatin rather than simvastatin. Direct LDL measurement may therefore have a particular role in monitoring patients on statin treatment. |
| | |
Authors:
|
T Sathyapalan; S L Atkin; E S Kilpatrick |
Related Documents
:
|
17368279 - Safety considerations with gastrointestinally active lipid-lowering drugs. 1516599 - Short- and long-term effects of lovastatin and pravastatin alone and in combination wit... 21105969 - 'trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dy... 17854789 - Comparing pharmacokinetic and pharmacodynamic profiles in female rats orally exposed to... 20086769 - Controlling blood lipids part 2: when and how to use medication. 12686019 - Use of statins for secondary prevention. 16864879 - Comparison of alternative beef production systems based on forage finishing or grain-fo... 14673639 - Consumption of salmon by alaskan brown bears: a trade-off between nutritional requireme... 7225169 - Studies on cholesterol ester hydrolysis in artificial lipid mixtures. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 12 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 540-4 Citation Subset: IM |
Affiliation:
|
Department of Diabetes, Endocrinology and Metabolism, Hull York Medical School, Hull, UK. tsathyapal@rediffmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C...
Next Document: Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weig...